Sling Therapeutics, based in Ann Arbor, MI, focuses on developing new therapies for thyroid eye disease (TED) and beyond. Their mission is centered on ensuring the maximum impact of their treatments by prioritizing the patient's well-being and adhering closely to scientific principles throughout their clinical development processes.
An integral part of Sling Therapeutics' pipeline is Linsitinib, an innovative oral therapy specifically designed to address the challenges faced by patients, caregivers, and medical professionals in the treatment of TED. This promising development aims to offer a more manageable and effective treatment solution for those affected by the disease.
The company is led by a dedicated team of executives, drug developers, and scientific advisors with extensive experience and a strong commitment to finding impactful solutions. Their collective expertise and unwavering dedication drive the continuous pursuit of innovative therapies that can make a real difference in the lives of patients.
Generated from the website content
